New approaches in the treatment of type 2 diabetes.
Type 2 diabetes is a chronic metabolic derangement that results from defects in both insulin action and secretion. New thiazolidinedione insulin sensitizers have been recently launched. New approaches with mechanisms different from current therapies are being explored, including novel ligands of peroxisome proliferator-activated receptor, glucagon receptor antagonists, dipeptidyl peptidase IV inhibitors, and insulin receptor activators.
Zhang
B B
BB
Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, NJ 07065, USA. bei_zhang@merck.com
Moller
D E
DE
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005934:Glucagon / Q000819:agonists; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008099:Liver / Q000502:physiology; D015394:Molecular Structure; D010446:Peptide Fragments / Q000819:agonists; D011498:Protein Precursors / Q000819:agonists; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors; D011972:Receptor, Insulin / Q000819:agonists; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors; D013844:Thiazoles / Q000494:pharmacology; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000378:metabolism
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011498:Protein Precursors; D018160:Receptors, Cytoplasmic and Nuclear; D018027:Receptors, Glucagon; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C089946:2,4-thiazolidinedione; D011972:Receptor, Insulin; D017027:Protein Tyrosine Phosphatases; D005947:Glucose